InnoCare Pharma Limited (OTCMKTS:INCPF – Get Free Report) was the target of a significant decline in short interest in June. As of June 15th, there was short interest totaling 445,268 shares, a decline of 63.0% from the May 31st total of 1,202,243 shares. Based on an average daily volume of 0 shares, the short-interest ratio is presently ∞ days.
InnoCare Pharma Price Performance
Shares of InnoCare Pharma stock remained flat at $1.55 on Monday. InnoCare Pharma has a 12-month low of $1.55 and a 12-month high of $2.31. The stock’s 50 day moving average price is $1.55 and its two-hundred day moving average price is $1.75.
Analysts Set New Price Targets
Separately, Morgan Stanley upgraded InnoCare Pharma to an “overweight” rating in a research note on Thursday, May 28th. One equities research analyst has rated the stock with a Buy rating, According to MarketBeat.com, the stock has an average rating of “Buy”.
About InnoCare Pharma
InnoCare Pharma Ltd is a China-based, clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small-molecule targeted therapies for oncology. Headquartered in Shenzhen, Guangdong Province, the company leverages structure-based drug design and comprehensive preclinical screening to advance drug candidates that address high-unmet-need cancers.
The company’s development pipeline comprises multiple small-molecule inhibitors in various stages of preclinical and early clinical evaluation.
See Also
- Five stocks we like better than InnoCare Pharma
- onsemi: What the Market Gets Wrong, You Can Get Right
- Is McCormick a Steal Ahead of Game-Changing Unilever Deal?
- Qualcomm’s Investor Day Just Changed the Growth Story Forever
- JPMorgan Stands by Sky-High Broadcom Target as Shares Slide
Receive News & Ratings for InnoCare Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InnoCare Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
